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Differential scanning ﬂuorimetryDeﬁciency of UDP-galactose 4′-epimerase is implicated in type III galactosemia. Two variants, p.K161N-
hGALE and p.D175N-hGALE, have been previously found in combination with other alleles in patients with
a mild form of the disease. Both variants were studied in vivo and in vitro and showed different levels of im-
pairment. p.K161N-hGALE was severely impaired with substantially reduced enzymatic activity, increased
thermal stability, reduced cofactor binding and no ability to rescue the galactose-sensitivity of gal10-null
yeast. Interestingly p.K161N-hGALE showed less impairment of activity with UDP-N-acetylgalactosamine in
comparison to UDP-galactose. Differential scanning ﬂuorimetry revealed that p.K161N-hGALE was more sta-
ble than the wild-type protein and only changed stability in the presence of UDP-N-acetylglucosamine and
NAD+. p.D175N-hGALE essentially rescued the galactose-sensitivity of gal10-null yeast, was less stable
than the wild-type protein but showed increased stability in the presence of substrates and cofactor. We pos-
tulate that p.K161N-hGALE causes its effects by abolishing an important interaction between the protein and
the cofactor, whereas p.D175N-hGALE is predicted to remove a stabilizing salt bridge between the ends of
two α-helices that contain residues that interact with NAD+. These results suggest that the cofactor binding
is dynamic and that its loss results in signiﬁcant structural changes that may be important in disease
causation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Galactosemia is an autosomal recessive disease that results from
impaired ability to metabolize the sugar galactose due to com-
promised expression or activity of the enzymes of the Leloir pathway
[1–4]. Patients may develop a pathology that includes failure to
thrive, vomiting, jaundice and sometimes bacterial infection in the
most severe cases [4]. In the long term, disabilities in learning, speech,
ovarian function, and movement can manifest [5–7]. The disease is
classiﬁed into three types that vary in severity, pathology and occur-
rence and depend on which enzyme is affected. Type I is associated
with galactose-1-phosphate uridylyltransferase deﬁciency (E.C. 2.7.7.12;onic acid; BS3, suberic acid
se 1-phosphate; Glc-1P, glucose
uanidine hydrochloride; hGALE,
NAD+, oxidized nicotinamide
e dinucleotide; NAD(H), nicotin-
; UDP-Gal, uridine diphosphate
alNAc, uridine diphosphate-N-
cetylglucosamine
: +44 28 9097 5877.
l rights reserved.OMIM#230400) and is the most commonly detected clinically severe
form [8]. The occurrence of this type is geographically dependent and
patients can show the most severe pathology of the three types. Over
230 different mutations have been detected by genetic screening, each
associated with varying degrees of impairment. These mutations
cause structural changes in the corresponding enzyme resulting in
less efﬁcient catalysis and/or reduced protein stability (for reviews see
[9–11]). Galactokinase deﬁciency (EC 2.7.1.6; OMIM# 230200) is impli-
cated in type II galactosemia [12] and this type is the least clinically se-
vere of the three. Patients tend to develop galactose-dependent early
onset cataracts and do not appear to suffer any other acute or long-
term complications [5,12].
Human UDP-galactose 4′-epimerase (E.C. 5.1.3.2; hGALE) ca-
talyses the inter-conversion of both UDP-galactose and UDP-N-
acetylgalactosamine to their glucose counterparts and contains a
bound NAD+ as an essential cofactor [3,13–16]. Deﬁciency of this en-
zyme is implicated in type III galactosemia (OMIM #230350) [17,18]
and this is the least understood form of galactosemia [2,19]. Only one
nonsense and 21 missense mutations of hGALE are known [20]. Origi-
nally, epimerase deﬁciency was identiﬁed as a biochemical oddity that
impacted only red and white blood cells in apparently healthy indi-
viduals ([21], and reviewed in [22]); this condition was termed
“peripheral” epimerase deﬁciency because it impacted only cells in
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liver, and even stimulated or EBV-transformed lymphoblasts, were not
affected (reviewed in [22]). Subsequently, rare patients were identiﬁed
whowere severely symptomatic anddemonstrated epimerase deﬁciency
in all cell types tested; these patients were said to have “generalized”
epimerase deﬁciency galactosemia [7]. Further studies of infants iden-
tiﬁed by newborn screening clearly established that there is a continuum
of biochemical phenotypes [23].
The GALE enzymes of Aeromonas hydrophila and Trypanosoma sp.
[24–26] are important in the viability of these pathogens, and GALE
is also essential for survival of the “model” multicellular eukaryote
Drosophila melanogaster [27]. The crystal structures of GALE from a
variety of different species interacting with various substrates and
substrate analogues are also known providing insight into how the
enzyme functions [15,16,28–31]. The human GALE structure has been
an invaluable tool in understanding how mutations can affect the en-
zyme and the structure of the variant associatedwith themost common
severe phenotype, p.V94M, has been solved [32]. Coupled with a yeast
model and biochemical work on the recombinant p.V94M protein, it
was revealed that this variant's lower activity was due to improper
binding of bothUDP- andUDP-N-acetyl- sugars and this caused elevated
galactose 1-phosphate levels in vivo [32,33]. Both the yeast model and
recombinant proteins have been used to dissect howeachmutation cau-
ses its effects. From these studies it has been shown that there is a corre-
lation between enzyme activity and the ability to rescue growth in
gal10-null yeast cells, which lack endogenous GALE [34–36]. Enzyme ac-
tivity also correlates inverselywith cellular Gal-1P accumulation [34,35],
and Gal-1P and UDP-Gal accumulation correlate inversely with growth
of gal10-null yeast [37]. The enzyme's turnover number (kcat) is reduced
in variant enzymes associated with type III galactosemia [20,38,39].
Biochemically, the stability of the enzyme is also important: decreased
stability and protein aggregation in vivo have been reported for some
of the disease-associated variants [20,34,38,40,41].
Here, both in vivo and in vitro approaches have been used to inves-
tigate two previously uncharacterized variants of hGALE, p.K161N and
p.D175N. Each corresponding allele was originally detected in the het-
erozygous state in patients who had been diagnosed biochemically
with a clinically benign form of epimerase deﬁciency [23]. Of note, the
patient who is heterozygous for hGALE.K161N is also heterozygous for
two intronic variants of unknown signiﬁcance [23], and the patient
who is heterozygous for hGALE.D175N is also heterozygous for two
silent substitutions of unknown signiﬁcance [23]. Parental DNAs were
unavailable, leaving linkage of the different variants in each patient
unclear. The relationship between functional signiﬁcance of the K161N
and D175N substitutions and the biochemical and clinical outcomes of
the patients who carry them is considered in Conclusions below.
Both the K161N and the D175N variants of hGALEwere investigated
for their ability to rescue gal10-null yeast, for the levels of internal
metabolites that accumulated in these yeast strains, and for enzyme
structure, stability, activity, and ability to bind substrates and the NAD+
cofactor. p.K161N-hGALE was found to be severely impaired while
p.D175N-hGALE was found to be only mildly affected. That the patient
carrying the K161N variant was nonetheless clinically mild may imply
that the other allele present in that patient remained functional, as is
discussed below. Results of stability studies and investigation of each
residue's location in the overall enzyme structure suggest altered con-
formations affect substrate and cofactor binding as well as stability.
2. Materials and methods
2.1. Expression and puriﬁcation of recombinant proteins in Escherichia
coli
Recombinant wild-type GALE proteins were expressed in E. coli and
puriﬁed as previously described [36,38]. The “QuikChange” protocol [42]
was used to change the appropriate codons in the expression vector.The following primers were used: hGALE.K161N for (5′-CCTTACGGC-
AAGTCCAATTTCTTCATCGAGGAA-3′) with hGALE.K161N rev (5′-TTCCTC-
GATGAAGAAATTGGACTTGCCGTAAGG-3′) and hGALE.D175N for (5′-
GACCTGTGCCAGGCAAACAAGACTTGGAACG TA-3′) with hGALE.D175N
rev (5′-TACGTTCCAAGTCTTGTTTGCCTGGCACAGGTC-3′). The sequences
were veriﬁed (MWG-Biotech, Ebersburg, Germany) and the mutated
plasmids were used to express p.K161N-hGALE and p.D175N-hGALE
using essentially the same protocol as used with the wild-type protein.
Recombinant human UDP-glucose dehydrogenase was expressed
and puriﬁed as previously described [36]. All protein concentrations
were determined using the Bradford assay [43] with bovine serum
albumin as a standard.
2.2. Measurement of the steady state kinetic parameters for
UDP-galactose 4′-epimerase
The activity of each puriﬁed variant protein was determined as
previously described [36]. Here the conversion of UDP-galactose to
UDP-glucose was measured by the UDP-glucose dehydrogenase cata-
lyzed oxidation of UDP-glucose by NAD+ [44]. Since the oxidation of
one molecule of UDP-glucose consumes two molecules of NAD+, the
rate of production of NADH, measured by absorbance at 340 nm, cor-
responds to twice the rate of production of UDP-glucose.
Initial rates of NADH production were determined from the linear
segment of each progress curve. Each rate was halved and then plotted
against the corresponding substrate concentration. The data were ﬁtted
to Eq. (1) using non-linear curve ﬁtting using GraphPad Prism (Gra-
phPad Software, CA, USA) with all points weighted equally.
v ¼ V max UDP Gal½ 
Km þ UDP Gal½ 
ð1Þ
where Vmax is the maximum, limiting rate and Km is the Michaelis
constant.
2.3. Biophysical characterisation of variant proteins
Chemical cross-linking with BS3 was carried out as previously de-
scribed [38,45]. Limited proteolysis was carried out as described [36]
with a fewmodiﬁcations. In addition to incubating with UDP-galactose,
protein sampleswere also incubatedwith 1 mMand 10 mMNAD+. The
amount of protection from limited proteolysis was analysed by 15%
SDS-PAGE. The ANS unfolding assay was carried out as previously de-
scribed [36].
2.4. Fluoresence spectra
Each hGALE variant (200 μl of 20 μM), dissolved in 10 mM HEPES,
pH 8.8 was aliquoted in triplicate into a black 96 well plate. Samples
were excited at 280 nm or 350 nm and emission was measured
from 300 to 510 nm or 400 to 500 nm respectively. All measurements
were done at room temperature using a Spectra Max Gemini X U.V.
plate reader ﬂuorimeter.
2.5. Plasmids and yeast strains
The p.K165N and p.D171N hGALE alleles were each re-created by
site-directed mutagenesis (Quikchange, Stratagene, Inc) of a wild-type
hGALE coding sequence within a low-copy-number yeast expression
plasmid, pMM33, as described previously [34]. The corresponding posi-
tive (wild-type hGALE) and negative (plasmid backbone only) controls
have been reported previously [34].
All yeast strains used in this study were derived by transformation
of JFy3835, a gal10-null haploid yeast strain that lacks endogenous
GALE, and that has been reported previously [35]. For enzyme assays,
yeast were cultured at 28 °C in synthetic medium containing 2%
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28 °C in synthetic medium containing 2% glycerol and 2% ethanol
(SGE), with or without the addition of galactose, as indicated.
2.6. Yeast protein lysates and enzyme assays
Yeast proteins were extracted by standard methods as previously
described [35,46] from 5 ml cultures grown to an OD600 between 0.8
and 1.2 in SD-Ura medium. Soluble protein extracts were placed over
P-6 Bio-Spin columns (Bio-Rad) to remove small metabolites prior to
further analysis. Protein determinations were made using the Bio-Rad
protein assay reagent, as recommended by the manufacturer, and
quantiﬁed using a standard curve of bovine serum albumin.
GALE enzyme activity was measured in soluble yeast lysates essen-
tially as previously described [33] with quantiﬁcation of reactants and
products by HPLC. For assays using UDP-Gal as substrate, initial reaction
conditions included 0.8 mM UDP-Gal, 40 mM glycine, 0.5 mM NAD+
and0.05 μg total soluble protein in aﬁnal volume of 12.5 μl. The reaction
was incubated at 30 °C for 30 min and stopped by addition of 187.5 μl of
chilled water. For assays using UDP-GalNAc as substrate, initial reaction
conditions included 40 mM glycine, 0.8 mM UDP-GalNAc, and 0.5 mM
NAD+with 0.3 μg soluble protein in a ﬁnal volume of 12.5 μl. Reactions
were carried out at 30 °C for 30 min and stopped by addition of 187.5 μl
chilled water. Samples were ﬁltered through 0.2 μm nylon ﬁlters
(Alltech) before HPLC analysis.
To test the relative dependence of p.K165N-hGALE and p.D171N-
hGALE on exogenous NAD+, analyses of soluble proteins from yeast
expressing either wild-type hGALE, p.K165N-hGALE, or p.D171N-
hGALE were performed in triplicate over a range of six different
NAD+ concentrations, as indicated; UDP-Gal and UDP-GalNAc were
each held constant at 0.8 mM.
The following procedures were used for separation and quantiﬁca-
tion of enzymatic substrates and products on a DX600 HPLC system
(Dionex, Sunnyvale, CA) consisting of a Dionex AS50 autosampler, a
Dionex GP50 gradient pump, and a Dionex ED50 electrochemical
detector, as previously described [47]. Samples were maintained at
4 °C in the autosampler tray and the chromatography was performed
at room temperature. Substrates and products was separated from
other metabolites on a CarboPac PA10 column (250×4 mm) with
an amino-trap (50×4 mm) placed before the analysis column and a
borate-trap (50×4 mm) placed before the injector port to remove
trace amounts of borate from the mobile phase. Elution programs
were as follows: For GALE (UDP-Gal), Solvent A: 10 mMNaOH; Solvent
B: 40 mMNaOH/200 mMNaAc. Solvents were degased andmaintained
under a helium atmosphere. An isocratic method was used with 35% A
and 65% B for 25 min at 0.8 ml/min ﬂow rate. UDP-Gal and UDP-Glc
were eluted at 17.6 and 20.5 min respectively. For GALE (UDP-GalNAc),
a similar isocratic method with the same solvent system was applied.
The method used 45% A and 55% B for 40 min at 0.75 ml/min ﬂow
rate. UDP-GalNAc and UDP-GlcNAc were eluted at 20.2 and 22.3 min
respectively.
2.7. Determination of growth in galactose
Yeast growth curveswere performed as described previously [39,45].
All yeast cultures were grown in SGE-Ura medium to mid-logarithmic
phase, at which point they were diluted to OD600=0.05 and allowed
one more doubling. Finally, cells were inoculated into the wells of a
96-well ﬂat-bottom plate (NalgeNunc International, Rochester, NY) at
a density of 5×105 cells/ml in 100 μl/well of SGE-Ura medium sup-
plemented with the indicated concentration(s) of galactose. The plate
was incubated for 40 h at 30 °C with continuous shaking between
OD630 absorbance readings, which occurred every 30 min. Incubation,
shaking, and absorbance readings were performed using a microplate
reader (Bio-Tek, model #EL808UI) run by KC junior software (Bio-Tek
Instruments, Winooski, VT).2.8. Measurement of intracellular metabolites in yeast
Yeast JFy3835 expressing either WT-hGALE, no hGALE, p.K165N-
hGALE, or p.D171N-hGALE, each from a centromeric expression plas-
mid, were grown in SGE-Ura medium at 28 °C to OD600 between 0.8
and 1, then diluted to OD600=0.05 in parallel sets of cultures and
allowed to double to OD600=0.1. Galactose was then added (t=0)
to a ﬁnal concentration of 0.01% to one culture from each pair.
10 ml of cell suspension from each culture were collected for analysis
of intracellular metabolites at t=0 h, 6 h, and 24 h. Extracts were
prepared as described previously [47]. In brief, 10 ml of yeast culture
were quenched in 20 ml of ice-cold 60% (v/v) methanol. Cells were
collected by centrifugation at 2000 rpm for 20 min at 4 °C, then trans-
ferred to microfuge tubes and washed once with 1 ml of sterile water.
Intracellular metabolites were extracted by vigorous agitation of the
cells for 45 min at 4 °C in chloroform: methanol: water, 4:2:1, with
a ﬁnal volume of 875 μl. The aqueous layer was collected after centri-
fugation at 2000 rpm in a microfuge for 20 min at 4 °C. The remaining
organic phase was back-extracted with 125 μl methanol and 125 μl
water. Corresponding aqueous layers were combined and dried under
vacuum without heat. Finally, dried metabolites were rehydrated with
sterile water to a concentration of 5 mg cell dry mass/ml and ﬁltered
through 0.2 μm nylon ﬁlters (Alltech) before HPLC analysis.
Gal-1P and Glc-1P were quantiﬁed using the same DX600 HPLC
system (Dionex, Sunnyvale, CA) with a CarboPac PA10 column
(250×4 mm). 20 μl of each samplewere injected. The followingmobile
phase solvents were used: Solvent A, 10 mM NaOH, and Solvent B,
40 mM NaOH/200 mM NaAc. Flow rate was maintained at1 ml/min.
Gal-1P and Glc-1P were detected using a low salt gradient procedure:
98% A and 2% B (−10 to 8 min), a linear increase of B to 30%
(8–15 min), a linear increase of B to 50% (15–25min), hold for 5 min
(25–30 min), a linear decrease of B to 2% (30 to 35 min).
UDP-Gal and UDP-Glc were quantiﬁed using the same HPLC and
solvent system with a high salt gradient procedure: 50% A and 50%
B (−5 to 5 min), a linear increase of B to 70% (5–22 min), hold for
5 min (22–27 min), a linear decrease of B to 50% (27 to 40 min).
2.9. Differential scanning ﬂuorimetry
Sypro orange (Sigma, Poole, UK), a ﬂuorescent protein dye, was
diluted from a 5000× solution (manufacturer's concentration deﬁni-
tion) into a 50× solution with 10 mM HEPES, pH 8.8. This stock solu-
tion was mixed well prior to each use. Recombinant protein samples
were diluted in 10 mM HEPES, pH 8.8 to a ﬁnal concentration of 5 μM
and 1 μl of 50× sypro orange was added. Any ligands used were diluted
in 10 mM HEPES, pH 8.8 and added to a ﬁnal concentration of 1 mM.
Reactions were set up in a total volume of 20 μl in 0.2 ml PCR tubes
and controls with no protein were always run alongside experimental
samples.
Samples were loaded into a Rotor-Gene Q cycler (Qiagen) and the
following protocol was used: High resolution melt run (460 nm
source, 510 nm detector), 25 °C to 95 °C ramp with a 1 °C rise for
each step and no gain optimisation. The melting temperatures, (Tm),
were calculated using the inbuilt analysis software.
One way ANOVA with Dunnett comparison test was used to deter-
mine the signiﬁcance of the difference in Tm due to substrate binding.
2.10. Computational analysis of mutant proteins
The cupsat server (http://cupsat.tu-bs.de/) was used to estimate
the predicted energy of unfolding [48] of both variants to add further
insight into any destabilising affects the two mutations have on the
structure. The crystal structure 1EK6 was used through this server
and the effects of each substitution on the structure were determined
by the thermal option.
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3.1. Steady-state kinetics of recombinant proteins: both variants have
impaired activity
To understand the consequences of these substitutions, p.K161N
and p.D175N variants of hGALE were expressed and puriﬁed using a
bacterial expression system. Each substituted protein was produced
to a similar yield (approximately 7.0 mg of recombinant protein per
litre of culture) and quality as the wild-type protein (Fig. 1a).
The ability of each variant to catalyse the conversion of UDP-Gal to
UDP-Glc was determined using a coupled enzyme assay (Table 1).
Both p.K161N- and p.D175N-hGALE had reduced overall activity in
comparison to the wild-type protein (WT). p.K161N-hGALE was
most severely affected and had only 0.5% of the turnover number
(kcat) of the WT, whereas p.D175N-hGALE had a kcat that was 43% of
the wild-type's value. The Km of p.D175N was essentially unaltered
compared to the wild-type enzyme, but for p.K161N-hGALE the
value was increased almost 10-fold.3.2. Both variants retain the ability to form dimers
Since hGALE is a homodimer in solution [3] it was thought that the
effects on enzyme activity might be due to disruption of the ability to
dimerize. The chemical cross-linker BS3 has been used previously to
determine if disease-associated variants of hGALE could dimerize
[38,45] and was employed here. Both p.K161N-hGALE and p.D175N-
hGALE formed detectable dimers (M.W.=76 kDa) and higher order
oligomers (that have been observed before [38,45]), as judged by
SDS-PAGE (Fig. 2a). Subtle affects on dimerization, however, cannot
be ruled out by this method but these results demonstrate that(c) 
(a) 
p.K
16
1N
45 
35 
 M  
66 
116 
WT p.
D1
75
N
25 
Asp-66 
  Asp-33 
Asn-37 
Tyr-157 
Lys-161 
  NADH 
(b
(d
Fig. 1. Puriﬁed recombinant hGALE variants from E. coliwith the location and interactions of
SDS-PAGE (10%) and seen by staining with Coomassie blue. M=molecular mass markers (
altered by the disease-associated mutations. Altered residues are shown as sphere models in
of the nicotinamide adenine dinucleotide cofactor and is one of ﬁve key residues which inter
α-helices at the dimer interface. The helix that contains Asp-175 also contains Lys-161which
nitrogen, oxygen and phosphate atoms in blue, red and orange respectively. Hydrogen bond
all ﬁgures. Structures were made in PyMol (www.pymol.org) using PDB entry: 1EK6 [15].these variants have the potential to form dimers in a manner similar
to the wild-type.
3.3. Both variants show altered susceptibility to denaturation by GuHCl
and protease digestion
Since both variants showed decreased activity it was thought that
instability might be a contributing factor. A number of mutants of
hGALE have been previously shown to have an increased susceptibility
to protease degradation [38,41,45].
An ANS unfolding assay and limited proteolytic degradation by
trypsin were used to gain insight into what effects each alteration had
on the overall structure (Fig. 2b, c). p.K161N and p.D175N were both
more susceptible than the wild-type protein to proteolytic digestion
but gained some protection in the presence of UDP-Gal. p.D175N-
hGALE showed little difference in response to denaturation by GuHCl
compared to WT. Interestingly, p.K161N appeared to be more stable
than the WT showing a greatest ﬂuorescence emission at 1.0 M GuHCl.
This variant also showed no shift in the concentration of GuHCl
corresponding to the maximum ﬂuorescence in the presence of UDP-
Gal, whereas both the WT and p.D175N-hGALE showed an upward shift
from 0.5 M to 1.0 M GuHCl (Fig. 2c). Comparing the ﬂuorescence signals
at 0.5 MGuHCl using the Student's t-test conﬁrmed these shifts to be sta-
tistically signiﬁcant for both WT and p.D175N-hGALE (WT: p=0.0026;
D175N: p=0.0152) and the increased stability of K161N compared to
WT (p=0.0010).
3.4. p.K161N has an altered ability to bind the NAD+ cofactor
Since both variants had decreased activity and altered stabilities it
was suggested that this may be, in part, due to altered cofactor binding.K161 
K161 
D175 
D175 
Lys-125 
Asp-175 
Lys-161 
NADH 
UDP-Glc 
) 
) 
Lys-161 and Asp-175 within the hGALE protein structure. (a)Proteins were resolved by
kDa). (b) The structure of the hGALE dimer showing the locations of the amino acids
grey. (c) Lys-161 interacts with the 2′- and 3′-hydroxyl groups of the riboside moiety
act with the cofactor. (d) Asp-175 forms a salt bridge with Asp-125 near the ends of two
interacts with the cofactor. Selected residues are shown as stick models in white with
s are shown as black dotted lines. NAD+ is colored yellow while UDP-glucose is cyan in
Table 1
Kinetic constants of recombinant wild-type and variant hGALE enzymes acting on
UDP-Gal.
Protein Km kcat kcat/Km
μM s-1 l mol−1 s−1
WTa 48±16 14±1 3.0±1.1×105
p.K161N 462±75 0.07±0.01 1.6±0.3×102
p.D175N 86±34 6.1±0.6 7.1±3.0×104
a The values of the wild-type enzyme were determined previously [36] and are
included here for comparison. Values are the means±SD; n=3.
Dimer 
Monomer 
WT p.K161N 
C P C P 
Trimer 
  WT  p.K161N 
C P C P 
GALE 
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U U
(a) 
(b) 
(c) 
− laG-PDU
 p.K161N 
p.D175N 
Fig. 2. Chemical cross-linking, limited proteolysis and chemical denaturation of hGALE vari
difference in their ability to form dimers in comparison to the wild-type protein. C, contro
(b) UDP-galactose partially protected the variants from proteolysis, to a similar extent to t
600 nM trypsin; U, protein digested with 600 nM trypsin in the presence of 1 mM UDP-g
by ANS ﬂuorescence. In the absence of UDP-galactose, a peak occurred at approximately 0
UDP-galactose. A similar shift was seen with the p.D175N-hGALE protein but not with p.K1
trations of GuHCl in the absence of protein. Each point represents the mean±SD; n=3.
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site (Fig. 1c) [15].
NAD(H)-containing epimerases have a unique ﬂuorescence spec-
trum where excitement at 280 nm results in two emission peaks: a
peak at 340 nm due to tryptophan emission and a much smaller peak
at 450 nm due to FRET from tryptophan to the bound cofactor [25].
The resulting ﬂuorescence spectra (Fig. 3a) showed that while the
wild-type and p.D175N show this expected pattern, the p.K161N vari-
ant demonstrated a greatly diminished peak at 450 nm. Direct excita-
tion of the bound cofactor at 340 nm was also carried out. Here WT
hGALE showed a concentration dependent increase in the 450 nm sig-
nal from the cofactor, validating this technique in determining cofactor
content (Fig. S1a). Comparison of the hGALE variants showed similar
ﬁndings to the FRET data with p.K161N having a greatly reduced signal
at 450 nm (Fig. S1b). Additionally, unlike the WT and p.D175N-hGALE25 
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in the presence of 1 and 10 mM NAD+ (Fig. 3b).3.5. Impact of the p.K161N and p.D175N substitutions on hGALE activity
measured in soluble yeast lysates
In order to further understand the different behaviours of the mu-
tants in vitro and in vivo, both p.K161N- and p.D175N-hGALE alleles
were expressed in a yeast model. GALE enzyme activity assays per-
formed on soluble lysates of yeast expressing individual human GALE
alleles in a null backgrounddemonstrated that p.K161N-hGALEhas sub-
stantially reduced enzyme activity relative to p.D175N-hGALE, and both
alleles demonstrated signiﬁcantly reduced GALE activity relative to the
positive control (Fig. 4a, b). This same result was obtained using both
UDP-Gal and UDP-GalNAc as substrates.
To test whether the apparent activity impairment might reﬂect re-
duced afﬁnity for NAD+,we repeated the enzyme activity assays holding
substrate concentrations constant and varying the level of exogenous
NAD+. As illustrated (Fig. 4c, d), the p.K161N-hGALE enzyme was
unresponsive to increased NAD+ when the substrate was UDP-Gal, but
demonstrated a striking NAD+-dependent rise in activity when the sub-
strate was UDP-GalNAc. In contrast, the p.D175N-hGALE enzyme was
marginally responsive to increased NAD+ when the substrate was
UDP-Gal, and strikingly responsive to increased NAD+ when the sub-
strate was UDP-GalNAc.3.6. Differential impact of the p.K161N and p.D175N substitutions on
hGALE function in living yeast
We have previously demonstrated a relationship between growth
rate of yeast exposed to galactose and function of the GALE allele(s)
they express (e.g. [34–36,39]). To explore the potential functional im-
pairment of the p.K161N- and p.D175N-hGALE alleles in living yeast
we applied this “growth test” (Fig. 5) and found that, indeed, both
substituted alleles demonstrated impaired function, and of the two,
p.K161N-hGALE was, by far, the more severely impaired. These re-
sults conﬁrm that the GALE impairment observed in soluble lysates
(Fig. 4) and puriﬁed enzyme (Table 1) is not a vagary of the in vitro
system, but reﬂects a true enzyme impairment that is also evident
in vivo.
3.7. Differential accumulation of intracellular metabolites in
galactose-exposed yeast expressing p.K161N-hGALE and p.D175N-hGALE
As a ﬁnal in vivo test of the p.K161N- and p.D175N-hGALE alleles,
we asked whether yeast expressing either of these alleles accumulate
abnormal levels of galactose metabolites when exposed to 0.01% (w/v)
galactose in culture (Fig. 6). As predicted from their growth (Fig. 5a),
none of the strains accumulated Gal-1P (Fig. 6a) when cultured in the
absence of galactose, and yeast expressing normal hGALE or p.D175N-
hGALE also demonstrated little, if any, Gal-1P accumulation even when
exposed to galactose (Fig. 6b). In contrast, yeast expressing p.K161N-
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deﬁcient yeast.
Cultured in synthetic glycerol-ethanol medium (SGE-Ura) lacking
galactose, yeast expressing normal hGALE or p.D175N-hGALE demon-
strated almost no accumulation of UDP-Gal (Fig. 6c), while yeast0%  Galactose 
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Fig. 7. p.K161N-hGALE showed a higher Tm than the wild-type protein, whereas
p.D175N-hGALE showed a lower Tm. (a) Melting proﬁles and melting temperatures
of WT, p.K161N-hGALE, and p.D175N-hGALE in the absence of substrates and cofactors.
(b) Melting proﬁles and melting temperatures of WT hGALE with and without 1 mM
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Controls contained no protein. Values represent mean±SD; n=3.
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p.K161N-hGALE accumulated substantial and persistent levels of UDP-
Gal. Intracellular levels of Glc-1P and UDP-Glc appeared insensitive to
galactose exposure in all four yeast strains (data not shown).
3.8. A thermal shift assay conﬁrms the different impairments of substrate
and cofactor binding for both hGALE variants
To further investigate these variants, differential scanning ﬂuo-
rimetry (DSF) was carried out on the recombinant proteins. This is a
technique that uses an extrinsic hydrophobic ﬂuorophore to detect
conformational changes due to increasing temperature [49]. Here a
dye that ﬂuoresces strongly when bound to hydrophobic residues is
mixed with a puriﬁed protein sample and the mixture is heated in a
real-time thermal cycler. The ﬂuorescence initially increases resulting
from the unfolding of the protein as more hydrophobic patches ap-
pear and then decreases when the protein unfolds into a random
coil. The melting temperature, Tm, is then calculated as the midpoint
between the maximum and initial minimum ﬂuorescence. When a
protein is in the presence of a ligand, additional interactions and in-
duced conformational changes due to binding can then be inferred
from the change in Tm (ΔTm) [50]. In addition, there is a good agree-
ment between the results from this technique and differential scan-
ning calorimetry [49]. However, when using this assay it is assumed
that the unfolding of the protein follows a two state process, that
the unfolded state does not bind to the ligands, and that the unfolding
process is irreversible under the conditions of the experiment [49,50].
Previously we have used this technique to assess the binding of puta-
tive activators to hGALE [51,52].
Initial computational analysis using the cupsat server suggested
that p.K161N-hGALE was a stabilising mutation with an estimated
free energy change of unfolding of 5.85 kJ/mol. p.D175N-hGALE, how-
ever, was predicted to be destabilising with an estimated free energy
change of unfolding of −6.53 kJ/mol. DSF was then used to investi-
gate the effects each alteration has on the stability of the protein
Table 2
Change of melting temperatures (ΔTm) of recombinant wild-type and variant hGALE enzymes in the presence of various ligands.
ΔTm (K) Substrate Cofactor
Variant UDP-Gal UDP-Glc UDP-GlcNAc NAD+ NADH
WT −0.3±1.2 −0.1±0.5 2.2±0.3*** 1.1±0.4** 0.5±0.5
p.K161N 0.7±0.5 −0.4±1.1 −0.9±0.3 0.6±0.3 0.4±0.4
p.D175N 3.0±0.5*** 3.0±0.5*** 6.5±0.3*** 5.5±0.5*** 4.2±0.4***
ΔTm (K) Substrate and cofactor
Variant NAD+ and UDP-Gal NAD+ and UDP-Glc NAD+ and UDP-GlcNAc NADH and UDP-Gal NADH and UDP-Glc NADH and UDP-GlcNAc
WT 3.4±0.4*** 3.4±0.4*** 6.7±0.5*** 8.3±0.5*** 8.3±0.4*** 12.0±0.3***
p.K161N −0.8±1.9 −0.6±0.6 −4.8±0.9*** −0.6±0.5 −0.3±0.6 −1.1±0.5
p.D175N 9.1±0.6*** 9.2±1.9*** 15.3±0.5*** 15.6±0.4*** 15.7±0.6*** 19.8±0.4***
All ligands were added to a ﬁnal concentration of 1 mM in 10 mM HEPES, pH 8.8. The change of melting temperature, ΔTm, for mutant stability and ligand binding were calculated
using Eqs. (2) and (3) respectively.
ΔTm ¼ Tmof variantð Þ− Tmof WTð Þ
ΔTm ¼ Tmof protein with ligandð Þ− Tmof protein without ligandð Þ
Tm and ΔTm values are the means±SD; n=3. **pb0.001, ***pb0.0001 (One way ANOVA with Dunnett comparison test).
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curves for each variant are shown in Fig. 7a, Tm values are presented
in Table S1 and ΔTm data are shown in Table 2. An example of the
shift in melting temperature of wild-type hGALE due to substrate
binding is shown in Fig. 7b. The melting temperatures were found
to be in good agreement with the computationally predicted results.
p.K161N-hGALE was more stable with Tm increased by 5.9 K com-
pared to the wild-type protein (Fig. 7a). The only signiﬁcant change
in stability was detected when this variant was in the presence of
UDP-GlcNAc and NAD+, which reduced the Tm by 4.8 K (Table 2).
p.D175N-hGALE was less stable with Tm reduced by 8.6 K compared
to thewild-type proteinwithout ligands (Fig. 7a). However, this variant
showed signiﬁcant changes in Tmwhen in the presence of all substrates
and cofactors individually, whereas the wild-type protein did not
(Table 2).
4. Discussion
4.1. p.K161N is the more severe substitution due to altered cofactor
binding
The p.K161N variant showed a substantially decreased activity for
UDP-Gal determined from yeast lysates (Fig. 4) and the puriﬁed protein
(Table 1). Coupled with the inability to rescue gal10-null yeast (Fig. 5)
and accumulation of the metabolites Gal-1P (Fig. 6b) and UDP-Gal
(Fig. 6d), these data demonstrate that p.K161N-hGALE is a severely
impaired variant. The altered Km for UDP-Gal and increased protease
degradation indicate this mutation may cause conformational changes
and this is quite similar to variants associated with themore severe dis-
ease phenotypes [38]. However, this mutant also showed greater
resistance to chemical denaturation and showed some activity with
UDP-GalNAc suggesting a more complex situation (Fig. 2). This is likely
to be due to altered cofactor binding as demonstrated by a much lower
FRET signal, lack of protection from protease by NAD+ (Fig. 3) and the
NAD+-dependent rise in activity with UDP-GalNAc but not with UDP-
Gal (Fig. 4c, d). The decreased FRET and directly excited cofactor signals
(Figs. 3, S1b) considered together with the limited proteolysis data sug-
gest that this altered cofactor binding decreases the cofactor content of
this variant under the conditions investigated.
In the DSF assay, when in the presence of each substrate and co-
factor alone, the wild-type hGALE protein showed only a signiﬁcant
change of stability with NAD+ and UDP-GlcNAc. However when both
the cofactor and a substrate were present together, a signiﬁcantincrease in stability was detected. Most likely, this increase results
from the structural change that has been postulated based on the crystal
structures in which the N- and C-terminal domains clamp over the
active site when substrate is present [15]. In addition, these stability
changes were more than additive when compared to the changes
resulting from the addition of substrate or cofactor alone. This demon-
strates that substrate and cofactor binding at an active site is synergistic.
We have previously observed that hGALE exhibits sigmoidal kinetic
behaviour at 24 °C, suggesting cooperative interactions between, as
well as within, the subunits [36]. Furthermore, the higher stability of
the enzyme with NADH and substrate compared to NAD+ with sub-
strate reﬂects previous studies where the NADH-bound enzyme has a
higher afﬁnity for substrates than the NAD+-bound enzyme [28].
Even larger changes in stability of the wild-type protein were detected
when UDP-GlcNAc was present, suggesting additional stabilising inter-
actions. This may be due to the small conformational change that was
seen in the crystal structure of the enzyme bound to UDP-GlcNAc [16].
p.K161N-hGALE was more stable and, unlike the wild-type protein,
showed no signiﬁcant changes in stability in the presence of both sub-
strate and cofactor except with UDP-GlcNAc and NAD+ together
(Table 2).
Lys-161 is located in the cofactor binding site (Fig. 1c) forming
hydrogen bonds with the 2′- and 3′- hydroxyl groups of the riboside
moiety of the NAD+ cofactor [15]. The corresponding residue has been
associated with maintaining enzyme activity [53] and is conserved in
the GALE proteins of yeast, E. coli, rat, and human, highlighting its im-
portance [23]. It is thought that this lysine increases the reactivity of
the cofactor by destabilising the nicotinamide ring [53]. Mutational
studies at this site of the enzymes from E. coli and A. hydrophila show
similar decreases in activity with differences in cofactor binding. The
E. coli mutants, K153M and K153A presented no changes in binding
while the A. hydrophila mutant K153N showed a decreased afﬁnity
[26,53]. These differences are due to the different number of interac-
tions that the bacterial and human epimerases have between the pro-
tein and cofactor. The E. coli enzyme has 19 hydrogen bonds whereas
the human enzyme has only 11 [15] and this is further supported by
the observation that hGALE requires external NAD+ for optimal activity
unlike the bacterial enzyme [40]. Additionally removal of the cofactor
causes aggregation of the E. coli GALE whereas this does not occur in
the human enzyme [15]. Taken together, these observations suggest
that NAD+ is less tightly bound to the human enzyme than to the bac-
terial ones and is exchangeable under the conditions of these experi-
ments. The higher stability of p.K161N-hGALE towards thermal and
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data suggests that this variant has a low cofactor content andmost like-
ly additional stabilising interactions occurring in the binding pocket
perhaps because the binding pocket has partially collapsed. These struc-
tural changes affect the UDP-Gal binding site, decreasing UDP-sugar
afﬁnity (Fig. 2c, Table 1) and increase overall sensitivity to proteases
(Figs. 2b, 3b). This possible collapse of the cofactor binding site appears
not to be reversible under the conditions of these experiments, except
in the presence of UDP-GlcNAc and NAD+. The observation that UDP-
GalNAc activity is dependent on NAD+ concentration (Fig. 4b, d) and
the stability changes of this mutant when UDP-GlcNAc is bound together
with NAD+ (Table 2) suggests that conformational changes at the sub-
strate binding site reciprocally affect the cofactor binding pocket. This ob-
servation further supports the hypothesis that additional interactions
withUDP-GlcNAc orUDP-GalNAc cause different conformational changes
compared to the binding of UDP-Glc or UDP-Gal. In the case of p.K161N-
hGALE, these additional interactions appear to be able to open the active
site, permit partial repopulation of the cofactor binding site and, thus,
reduce the overall rigidity of the enzyme.
4.2. p.D175N is a mild variant due to the stability of the protein
The less severe enzymological impairment of p.D175N-hGALE,
compared to p.K161N-hGALE, suggests that less radical conforma-
tional changes have occurred. This variant showed no signiﬁcant differ-
ences from the wild-type protein in terms of chemical denaturation
(Fig. 2c) and cofactor binding (Figs. 3, S1b). Additionally, in vivo, yeast
expressing p.D175N-hGALE showed only a slight impairment of growth
when challenged with galactose (Fig. 5) and only a transient UDP-Gal
accumulation (Fig. 6) and intermediate levels of activity for both sub-
strates (Fig. 4). These results are consistent with p.D175N-hGALE
being an intermediately impaired enzyme.
However this variant appeared to be more prone to digestion
(Fig. 2b) and, in the more sensitive DSF assay, p.D175N-hGALE was
found to be less stable than the WT protein by 8.6 K (Fig. 7a, Table 2).
Also, signiﬁcant changes in stability in the presence of all substrates
and cofactors were detected and even larger changes in stability oc-
curred in the presence of both substrate and cofactor pairs (Table 2).
These results indicate a stabilising interaction being disrupted but the
resulting structural changes can be compensated by additional interac-
tions caused by cofactor and substrate binding. Additionally, the ﬁnding
that the stability of this variant is quite close to that of the wild-type
protein when cofactor and substrate are both bound (Table S1) sup-
ports the hypothesis that this protein is only slightly different from
the wild-type protein in conformation.
Asp-175 is located towards the end of anα-helix in the N-terminal
domain (Fig. 1d) and this forms a salt bridge with Lys-125 that is close
to the end of an adjacent α-helix [15]. Interestingly, Lys-161 is located
in one of these helices (Fig. 1d). Changing an aspartate to asparagine
will remove this salt bridge, most likely resulting in a reduction in sta-
bility. Our results support this hypothesis but also suggest that this
salt-bridge is only marginally important in maintaining overall struc-
ture, possibly helping maintain these α-helices in position.
4.3. Conclusions
The p.K161N and p.D175Nmutations were found in two unrelated
patients, each with the peripheral form of epimerase-deﬁcient galac-
tosemia [23]. Detailed biochemical analyses in vivo and in vitro have
revealed that the K161N and D175N substitutions lead to very differ-
ent levels of hGALE impairment. It is important to point out that both
alleles were found in the heterozygous state, not the homozygous
state, in their respective patients [23]. The patient who is heterozy-
gous for hGALE.K161N is also heterozygous for two intronic variants
of unknown signiﬁcance, and the patient who is heterozygous for
hGALE.D175N is also heterozygous for two silent substitutions ofunknown signiﬁcance [23]. Parental DNAs were unavailable for both
patients, leaving linkage of the different variants in each patient
unclear. Nonetheless, given the compound heterozygous nature of
the alleles in both patients that an apparently “severe” substitution
(K161N) could be found in a mildly affected patient suggests that
the other allele in that patient is likely to retain signiﬁcant function.
In this way, p.K161N is, functionally, quite similar to the p.G90E
variant [38]. p.G90E was also detected in a patient who was a com-
pound heterozygote and presented biochemically and clinically with
the benign, peripheral form of epimerase deﬁciency [1]. Glycine 90
is near the cofactor binding site and its mutation has been proposed
to perturb NAD+ binding [38]. Altered cofactor binding has also
been found before for one variant, p.N34S, but not for others
[40,46]. We cannot rule out the possibility that the mutations studied
here cause increased aggregation in vivo as previously observed with
some mutants expressed in mammalian GALE-null cells [41]. Coupled
with these ﬁndings, this suggests the possibility of developing a mo-
lecular chaperone treatment similar to that for phenylketonuria and
other misfolding diseases [54–57].
In summary we have determined the biochemical basis of impair-
ment of hGALE due to the two substitution mutations, p.K161N and
p.D175N. These studies have conﬁrmed that the impairment of the
two activities of hGALE, toward UDP-Gal and UDP-GalNAc, may not
be strictly correlated and that altered cofactor binding can affect
stability as well as activity. They also demonstrate that UDP-galactose
4′-epimerase requires the correct level of ﬂexibility for proper function.
An increase or decrease in ﬂexibility, as seen here with p.D175N and
p.K161N respectively, results in loss of function. It also cannot be
ruled out thatmore subtle affects are occurring in terms of dimerization
and that these may be important in the enzyme's possible communica-
tion between the two active sites. We recommend that future research
on all known and new variants should consider the role of cofactor
binding in the stability and structure and ﬂexibility of the protein in
the presence of both substrates. This will add further insight into the
relationship between speciﬁc hGALE mutations and different forms of
the disease epimerase-deﬁciency galactosemia.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.05.007.Acknowledgments
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